MISSOULA, Montana, April 1, 2024 – Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will present a talk titled ” Alternative uses for adjuvants & cross-over immunotherapy technologies” at the World Vaccine Congress, in Washington DC on April 1-4.
The World Vaccine Congress is the worlds leading vaccine event bringing together experts in vaccinology and immunology from academia, government, and industry. Dr. Evans will provide an update on Inimmune’s clinical stage vaccine adjuvant and innovative immunotherapy programs on April 1, 2024 during the Vaccine Technologies Workshop and this work will be featured during panelist discussions moderated by Dr. Evans, on vaccines and global health resilience.
Vaccine adjuvants, like those being developed at Inimmune, are used to enhance the immune response to vaccines. Adjuvants are also important stand-alone immunomodulators in other areas of medicine, such as immunooncology, allergy, and autoimmunity. Inimmune is focused on developing innovative vaccine adjuvants and delivery systems to enhance global health with a rapidly growing pipeline of innovative immunotherapeutics.
